Danaher [DHR] vs Idexx Laboratories [IDXX] Detailed Stock Comparison
Danaher
NYSE
Loading...
Idexx Laboratories
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Danaher wins in 10 metrics, Idexx Laboratories wins in 9 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Danaher | Idexx Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.88 | 54.06 | Danaher |
| Price-to-Book Ratio | 2.89 | 35.76 | Danaher |
| Debt-to-Equity Ratio | 35.45 | 84.81 | Danaher |
| PEG Ratio | -1.20 | 1.11 | Danaher |
| EV/EBITDA | 22.16 | 38.16 | Danaher |
| Profit Margin (TTM) | 14.21% | 24.41% | Idexx Laboratories |
| Operating Margin (TTM) | 20.12% | 33.62% | Idexx Laboratories |
| EBITDA Margin (TTM) | 20.12% | 33.62% | Idexx Laboratories |
| Return on Equity | 6.68% | 64.87% | Idexx Laboratories |
| Return on Assets (TTM) | 4.01% | 23.26% | Idexx Laboratories |
| Free Cash Flow (TTM) | $5.30B | $798.08M | Danaher |
| 1-Year Return | -21.68% | 32.21% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 6.29 | 12.90 | Danaher |
| Enterprise Value | $166.64B | $53.14B | Danaher |
| EV/Revenue Ratio | 6.94 | 13.16 | Danaher |
| Gross Profit Margin (TTM) | 59.35% | 62.62% | Idexx Laboratories |
| Revenue per Share (TTM) | $33 | $50 | Idexx Laboratories |
| Earnings per Share (Diluted) | $4.70 | $12.04 | Idexx Laboratories |
| Beta (Stock Volatility) | 0.76 | 1.50 | Danaher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Danaher vs Idexx Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Danaher | 0.34% | 5.17% | 9.37% | 10.46% | 3.13% | -8.22% |
| Idexx Laboratories | -0.48% | -1.10% | 23.58% | 27.12% | 44.93% | 59.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Danaher | -21.68% | -18.64% | 14.50% | 260.93% | 763.76% | 1,053.88% |
| Idexx Laboratories | 32.21% | 74.14% | 69.73% | 777.14% | 2,182.05% | 4,061.38% |
Performance & Financial Health Analysis: Danaher vs Idexx Laboratories
| Metric | DHR | IDXX |
|---|---|---|
| Market Information | ||
| Market Cap | $151.04B | $52.07B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 3,241,650 | 983,296 |
| 90 Day Avg. Volume | 4,189,007 | 698,835 |
| Last Close | $210.93 | $650.84 |
| 52 Week Range | $171.00 - $279.90 | $356.14 - $688.12 |
| % from 52W High | -24.64% | -5.42% |
| All-Time High | $296.06 (Sep 06, 2021) | $706.95 (Jul 26, 2021) |
| % from All-Time High | -28.75% | -7.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.11% |
| Quarterly Earnings Growth | -0.39% | 0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.24% |
| Operating Margin (TTM) | 0.20% | 0.34% |
| Return on Equity (TTM) | 0.07% | 0.65% |
| Debt to Equity (MRQ) | 35.45 | 84.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $73.10 | $18.20 |
| Cash per Share (MRQ) | $4.13 | $2.06 |
| Operating Cash Flow (TTM) | $6.17B | $905.81M |
| Levered Free Cash Flow (TTM) | $3.88B | $625.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Danaher vs Idexx Laboratories
| Metric | DHR | IDXX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.88 | 54.06 |
| Forward P/E | 25.17 | 54.42 |
| PEG Ratio | -1.20 | 1.11 |
| Price to Sales (TTM) | 6.29 | 12.90 |
| Price to Book (MRQ) | 2.89 | 35.76 |
| Market Capitalization | ||
| Market Capitalization | $151.04B | $52.07B |
| Enterprise Value | $166.64B | $53.14B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.94 | 13.16 |
| Enterprise to EBITDA | 22.16 | 38.16 |
| Risk & Other Metrics | ||
| Beta | 0.76 | 1.50 |
| Book Value per Share (MRQ) | $73.10 | $18.20 |
Financial Statements Comparison: Danaher vs Idexx Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DHR | IDXX |
|---|---|---|
| Revenue/Sales | $5.74B | $998.43M |
| Cost of Goods Sold | $2.23B | $375.05M |
| Gross Profit | $3.51B | $623.38M |
| Research & Development | $379.00M | $59.06M |
| Operating Income (EBIT) | $1.27B | $316.53M |
| EBITDA | $1.87B | $351.81M |
| Pre-Tax Income | $1.13B | $310.08M |
| Income Tax | $175.00M | $67.41M |
| Net Income (Profit) | $954.00M | $242.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DHR | IDXX |
|---|---|---|
| Cash & Equivalents | $1.99B | $163.97M |
| Total Current Assets | $9.53B | $1.32B |
| Total Current Liabilities | $6.65B | $1.14B |
| Long-Term Debt | $15.98B | $546.80M |
| Total Shareholders Equity | $50.86B | $1.45B |
| Retained Earnings | $44.91B | $5.58B |
| Property, Plant & Equipment | N/A | $833.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DHR | IDXX |
|---|---|---|
| Operating Cash Flow | $1.47B | $235.07M |
| Capital Expenditures | $-239.00M | $-30.03M |
| Free Cash Flow | $1.05B | $207.94M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-1.08B | $-400.89M |
Short Interest & Institutional Ownership Analysis
| Metric | DHR | IDXX |
|---|---|---|
| Shares Short | 8.45M | 2.48M |
| Short Ratio | 1.93 | 4.68 |
| Short % of Float | 0.01% | 0.04% |
| Average Daily Volume (10 Day) | 3,241,650 | 983,296 |
| Average Daily Volume (90 Day) | 4,189,007 | 698,835 |
| Shares Outstanding | 719.10M | 81.60M |
| Float Shares | 637.22M | 79.13M |
| % Held by Insiders | 0.11% | 0.01% |
| % Held by Institutions | 0.83% | 0.98% |
Dividend Analysis & Yield Comparison: Danaher vs Idexx Laboratories
| Metric | DHR | IDXX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |